Rafael Holdings (RFL) as of January 31, 2026 presents a balance sheet where equity recovery to common shareholders is positive under liquidation but materially constrained by the composition of assets. Total assets are $99.3M against total liabilities of $16.1M, yielding GAAP book equity attributable to RFL of $79.2M. Under liquidation haircuts, the recovery picture is dominated by a $37.8M cash position (100% recoverable) and $1.9M in convertible notes receivable classified as available-for-sale (fair value, effectively liquid). These two items alone account for approximately $39.7M in high-confidence recoverable value. Against total liabilities at face value of $16.1M ($12.4M current, $3.7M non-current), the residual to all equity holders is approximately $23-24M before any haircuts on non-cash assets — consistent with MFFAIS CLV/LLV estimates of approximately $25.4M-$25.7M. The $39.7M in cash/near-cash is partially offset by a significant intangible and goodwill load: goodwill of $19.9M (zero recovery under liquidation lens) and finite-lived intangibles net of $0.9M (zero recovery). PP&E net of $1.5M recovers at 50-70%, or roughly $0.8M-$1.1M. Inventory of $0.3M recovers at 60%, approximately $0.2M. The liability stack is modest and manageable: accounts payable $8.2M, accrued liabilities $2.8M current, convertible notes payable current $0.6M, and non-current accrued liabilities $3.5M. Convertible notes long-term are negligible at $0.05M. The primary driver of equity erosion since July 31, 2025 is cash burn: cash fell from $52.8M to $37.8M (-$15.0M) over the six-month period, entirely from operating cash outflows of $14.3M driven by the Cyclo Therapeutics subsidiary consolidated post-March 2025 merger, which contributed $10.4M of the $12.0M total H1 FY2026 R&D spend. Working capital contracted from $45.1M to $30.1M. Goodwill of $19.9M is entirely healthcare-segment related; the Infusion Technology segment's goodwill was fully impaired ($3.1M charge) in Q2 FY2025. A material weakness in internal controls at Cyclo related to accrual recognition has been disclosed and remediation is in-process, creating modest uncertainty around the reliability of accrued expense balances, particularly clinical trial accruals. The LipoMedix convertible notes receivable ($1.9M, Level 3 fair value) are not separately liquid and their recovery in liquidation is uncertain. MFFAIS OLV of $26.0M implies minimal additional going-concern premium over liquidation value.
▼ Community Notes